Latest Trials Latest NewsFAQ

GILEAD SCIENCES SL

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA

Completed

Conditions: Pre-exposure Prophylaxis for Prevention of HIV Infection

First Posted Date: 2013-05-31

Last Posted Date: 2018-03-27

Lead Sponsor: Gilead Sciences

Target Recruit Count: 64186

Registration Number: NCT01865799

Locations: 🇺🇸
Gilead Sciences, Inc., Foster City, California, United States

A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP Indication

Completed

Conditions: HIV Infection

First Posted Date: 2013-05-31

Last Posted Date: 2018-03-30

Lead Sponsor: Gilead Sciences

Target Recruit Count: 99

Registration Number: NCT01865786

Locations: 🇺🇸
Antiretroviral Pregnancy Registry, Wilmington, North Carolina, United States

Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection

Phase 2

Completed

Conditions: Hepatitis C

Interventions: Drug: SOF
Drug: VEL
Drug: RBV

First Posted Date: 2013-05-21

Last Posted Date: 2018-11-14

Lead Sponsor: Gilead Sciences

Target Recruit Count: 379

Registration Number: NCT01858766

Locations: 🇺🇸
VA Long Beach Healthcare System, Long Beach, California, United States
🇺🇸
University of Florida Center for Clinical Trials Research, Gainesville, Florida, United States
🇺🇸
ID Care, Hillsborough, New Jersey, United States

and more 48 locations

Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

Phase 2

Active, not recruiting

Conditions: Acquired Immune Deficiency Syndrome (AIDS)
HIV Infections

Interventions: Drug: E/C/F/TAF
Drug: E/C/F/TAF (Low Dose)

First Posted Date: 2013-05-16

Last Posted Date: 2024-10-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 129

Registration Number: NCT01854775

Locations: 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇿🇦
Desmond Tutu HIV Foundation, Cape Town, South Africa

and more 13 locations

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Phase 3

Completed

Conditions: Chronic Hepatitis C Virus

Interventions: Drug: LDV/SOF
Drug: RBV

First Posted Date: 2013-05-10

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 647

Registration Number: NCT01851330

A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects

Completed

Conditions: HIV Infections

First Posted Date: 2013-05-09

Last Posted Date: 2014-10-31

Lead Sponsor: Gilead Sciences

Target Recruit Count: 476

Registration Number: NCT01850212

Locations: 🇩🇪
Universitäts-Hautklinik Essen, Essen, Germany
🇩🇪
Universitatsklinik Koln (AöR), Koln, Germany
🇩🇪
Klinikum der Universität München-Großhadern, Munchen, Germany

and more 70 locations

Study of the Effect of GS-6615 in Subjects With LQT-3

Phase 1

Completed

Conditions: Long QT Syndrome

Interventions: Drug: GS-6615

First Posted Date: 2013-05-08

Last Posted Date: 2014-11-17

Lead Sponsor: Gilead Sciences

Target Recruit Count: 24

Registration Number: NCT01849003

Locations: 🇺🇸
University of Rochester Medical Center/Strong Memorial Hospital, Rochester, New York, United States

A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects

Phase 1

Completed

Conditions: Ischemic Heart Disease

Interventions: Drug: GS-6615
Drug: Placebo

First Posted Date: 2013-05-06

Last Posted Date: 2013-11-13

Lead Sponsor: Gilead Sciences

Target Recruit Count: 36

Registration Number: NCT01847391

Locations: 🇺🇸
Investigational Site, Madison, Wisconsin, United States

Phase Ib Study of SC Milatuzumab in SLE

Phase 1

Completed

Conditions: Lupus Nephritis
Lupus Erythematosus, Cutaneous
Lupus Erythematosus, Systemic
Lupus Erythematosus, Discoid
Lupus Vasculitis, Central Nervous System

Interventions: Drug: milatuzumab
Drug: Placebo

First Posted Date: 2013-05-03

Last Posted Date: 2021-08-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 22

Registration Number: NCT01845740

Locations: 🇺🇸
Cedars Sinai Medical Center-Wallace Rheumatic Study Center, West Hollywood, California, United States

A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Ranolazine
Drug: Placebo
Drug: Exenatide

First Posted Date: 2013-04-30

Last Posted Date: 2014-03-31

Lead Sponsor: Gilead Sciences

Target Recruit Count: 24

Registration Number: NCT01843127

Locations: 🇺🇸
Profil Institute for Clinical Research, Inc., Chula Vista, California, United States
🇺🇸
Translational Research Institute-Florida Hospital, Orlando, Florida, United States
🇺🇸
SeaView Research, Inc, Miami, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy